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CHAPTER ONE

INTRODUCTION

1.1

Tyrosinemia
Enzymatic dysfunctions involving the metabolism of an amino acid, the monomeric

unit of proteins, results in severe pathologies coined aminoacidopathies. A lesser-known
representative of this category, tyrosinemia, is a disease that affects the catabolic pathway
of the amino acid tyrosine. This inborn error of metabolism consists of an enzymatic
deficiency and/or dysfunction along the main degradation pathway, which prevents the
breakdown of tyrosine. The resulting accumulation of tyrosine and/or its metabolites is
dependent on which enzyme the individual lacks along the pathway and can govern the
prognosis and treatment plan of the patient. Currently there are three types of
tyrosinemia documented, termed types I, II, and III. All involve the absence or
dysfunction of an enzyme along the catabolic pathway of tyrosine, and each has their
own associated phenotypes.
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1.1.1 Tyrosinemia Type I
The most common type of Tyrosinemia, Tyrosinemia Type I (TTI), has been
coined “hepatorenal tyrosinemia” because the disease primarily affects the liver and
kidneys, with some recently reported neurological involvement. Also classified as the
most severe, individuals afflicted with the disease have a mutation in the
fumarylacetoacetase (FAH) gene. This leads to a lack of functional FAH, which is a
necessary enzyme in the tyrosine breakdown pathway shown in Figure 1.1.
There have been multiple independent mutations in the FAH gene identified as
causative agents of TTI, all of which are of autosomal recessive inheritance (Grompe,
1994). TTI is most commonly found in the French Canadian ethnicity, with of an
incidence of around 1 in 12,000. This can be compared to the normal population
incidence of about 1 in 100,000 (Grompe, 1994). People in the Saguenay-Lac-Saint-Jean
region of Quebec are the most susceptible to the disease. Due to the Founder Effect, it is
estimated that as many as 1 in 56 people from this region are carriers of TTI, and
consequently they have the highest incidence of 1 in 1,846 (Grompe, 1994). In turn,
Grompe expected that most of the French Canadian population that was afflicted with the
disease had a common mutation. Following a study on this particular population, he
found that 69% of the patients in his study indeed were homozygous for a splice site
mutation found in intron 12 of the FAH gene (Grompe, 1994). This particular mutation
leads to a complete knock out of the gene, so no FAH production is expected.
Because of the nature of the position of the FAH mutation in the pathway, there is
a buildup of toxic intermediates, mainly succinylacetone (SA) and fumarylacetoacetate
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Figure 1.1: The Catabolic Pathway of Tyrosine and the Three Types of Tyrosinemia
Tyrosine is first converted to 4-hydroxyphenyl pyruvate (4-hpp) via tyrosine
aminotransferase (TAT). In individuals with Tyrosinemia Type II, this TAT enzyme is
missing and/or deficient. 4-hpp is further modified by 4- Hydroxyphenylpyruvate
dioxygenase (4-HPPD), deficient in Tyrosinemia Type III patients, to form
homogentisate. Homogentisate 1,2-dioxygenase (HGD) converts homogentisate to
maleylacetoacetate. Next maleylacetoacetate is converted to fumarylacetoacetate, which
is further broken down into fumarate and acetoacetate by Fumarylacetoacetase (FAH).
FAH is deficient in TT1 patients, leading to the formation of toxic metabolites
fumarylacetoacetate (FAA) and succinylacetone (SA). NTBC works by blocking the 4HPPD enzyme and eliminating the formation of FAA and SA in TT1.
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(FAA), shown in Figure 1.1. (Grompe, 1994). Both of these compounds have been
shown to be highly reactive, and are proposed to be the main contributors to TTI
symptoms. Specifically, FAA accumulates in hepatocytes and the proximal renal tubal
cells of the kidney, causing DNA and oxidative damage (Bliksurd et al., 2013). In
addition, because of the high levels of FAA present in the body, negative feedback loops
will slow the breakdown of tyrosine, leading to additional increases of tyrosine in the
body. In addition to the effects of FAA, SA accumulates in TT1 patients leading to
additional physiological effects. SA has been shown to be a potent inhibitor of heme
biosynthesis due to its structural similarity to δ-aminolevulinic acid (ALA), a compound
included in porphyrin synthesis (Sassa & Kappas, 1983). Heme is very important to
brain functioning and a deficiency in heme in the brain leads to cell death in the neuronal
cell line PC-12 (Sengupta et al., 2005).
TT1 can present either as acute or chronic, and the characterization of the disease
could be related to residual FAH activity. Acute symptoms of the disease range from
fever, vomiting, diarrhea, jaundice, and progressive liver disease. Most children perish
within a year from liver failure without treatment. The chronic form of the disease is not
as severe and can result in hypophosphatemic rickets, hepatoma, and polyneuropathy, but
children still do not usually survive a decade without intervention. Due to the severity of
the disease, in recent years, there has been a campaign to expand the newborn screening
for TT1 to all of the United States, using SA as a biomarker. This has been made
possible because of advances in TT1 research, and the development of a reliable,
inexpensive biochemical assay to test for SA in a dried blood spot from a newborn’s heel.
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The effects of SA and FAA are so severe in TT1 patients that the development of
a drug preventing these effects was imperative to their survival. The Food and Drug
Administration (FDA) approved a previously used herbicide Nitisinone (NTBC) as a
treatment for TT1. NTBC is a known inhibiter of 4-hydroxylphenylpyruvate dioxygenase
(4-HPPD), another enzyme present in the tyrosine breakdown pathway shown in Figure
1.1. The drug’s action halts the breakdown of tyrosine upstream from the previous
mutation, thereby eliminating the production of the toxic metabolites, SA and FAA. As
of today, the current treatment recommendations for TT1 patients are NTBC coupled
with a modified diet low in tyrosine and phenylalanine, or when NTBC resistant, a liver
transplant. Each treatment has its own associated risk.
Before the release of NTBC and the implementation of newborn screening, the
prognosis for those diagnosed with TTI was very poor. Most infants were unable to
thrive and classically presented with hepatomegaly, an enlarged liver. Although the
numbers are not concrete, it is likely that some cases of Sudden Infant Death Syndrome
(SIDS) could have been attributed to TTI (Barnby, 2014). Before NTBC approval,
infants with TT1 did not survive into adulthood, so there is no long-term data on how TTI
manifests in adolescence and adulthood. Because of the substantial increase in DNA and
oxidative damage in hepatocytes due to accumulation of FAA, there is an increased risk
for TT1 patients to develop hepatocellular carcinoma (Bliksurd et al., 2013). Liver
transplantations are very common in order for TTI patients to thrive, but the transplants
do not last forever, and patients are left with taking anti-rejection drugs for the remainder
of their life. Therefore, in order for TT1 patients to really thrive, the development of
additional therapies was essential.
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1.1.2 Tyrosinemia Type II and Tyrosinemia Type III
The other two types of tyrosinemia are not as common as TTI, but their effects are
just as substantial. In type II, also termed “oculocutaneous” because of the eye and skin
involvement, individuals lack the tyrosine aminotransferase (TAT) enzyme, the ratelimiting enzyme of the catabolic pathway of tyrosine illustrated in Figure 1.1. As a result
of where the enzymatic defect is located in the pathway, these patients display
characteristically high levels of tyrosine in their serum. Tyrosine, the type II biomarker,
accumulates in the eyes, leading to corneal lesion and/or glaucoma over time. In
addition, these patients suffer from keratinized skin lesions most commonly found on the
soles of the feet and palms. Unfortunately, some patients do have signs of mild to
moderate mental disability, language defects, and fine motor disturbances (Ferreira et. al.,
2011).
The third type, and least documented of all, is caused by a deficiency in the
second enzyme in the catabolic pathway, 4-HPPD, illustrated in Figure 1.1. Research in
type III tyrosinemia is of special interest to those that are studying NTBC, because NTBC
blocks the same enzyme that is mutated in type III patients. Essentially those on NTBC
pharmacotherapy display a tyrosinemia type III phenotype. This is the most rare of all
tyrosinemia cases documented. The majority of patients have normal functioning of the
eyes, skin, liver, and kidneys; (Ellaway et al, 2001) however, most patients will exhibit
some type of neurological symptoms ranging from delayed motor development to
learning difficulties and intellectual impairments (Ellaway et al, 2001). A summary of all
three types of tyrosinemia can be found in Table 1.1.
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Table 1.1
Summary of Tyrosinemia Types
Type

Affected Gene

Biochemical

Affected Organs

Consequence
I

! Tyrosine

FAH

!

Succinylacetone

!
II

!

TAT

Mainly Liver
Kidneys
Brain

FAA
Tyrosine

Eyes / Skin
Brain

III

!

4-HPPD

7

Tyrosine

Brain

1.2

Nitisinone (NTBC)
Originally discovered in 1982 by Zeneca Agrochemical Products, 2-(2-nitro-4-

trifluoromethylbenzoyl)-1,3-cyclohexanedione, or nitisinone (NTBC), initially was
developed as an herbicide (Lock et al, 1998). Classified as a triketone, this molecule is a
naturally occurring chemical that can be found in plant oils and is classified as a broad
spectrum bleaching herbicide (Lock et al, 1998). With a measured half-life in vitro of 63
hours, NTBC is reversibly bound to 4-HPPD in a rapid inactivation step, followed by a
slowed dissociation from the enzyme leading researchers to conclude that NTBC was
binding directly to the active site (Lock et al, 1998). Researchers at the Zeneca lab were
interested in the effect of this herbicide on animals and after administering NTBC to rats,
discovered that their urine contained tyrosine metabolites (Lock et al, 1998). Upon
further research, the scientists at Zeneca determined that NTBC was an inhibitor of 4HPPD (Lock et al, 1998). Following research on dosage, it was discovered NTBC has
relatively low acute oral toxicity. However after only 90 days on the drug, rats and dogs
developed various eye conditions including corneal lesions that were resolved after
NTBC treatment was stopped (Lock et al, 1998). In addition, high plasma tyrosine levels
were found in the liver and eyes. Based on previous observations, it was acknowledged
that the high tyrosine levels could be responsible for the molecular mechanisms of the
symptoms (Lock et al, 1998). Unfortunately, before long-term data could be reached on
the rats being administered NTBC over one year, the program was cancelled because
NTBC was no longer being developed as an herbicide (Lock et al, 1998).
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Figure 1.2: The chemical structure of Nitisinone (NTBC).
2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione, or nitisinone (NTBC) is a
triketone, originally developed as a broad spectrum bleaching herbicide. A potent
inhibitor of the 4-HPPD enzyme, NTBC has now been patented as Orfadin® for use for
treatment for TT1. (CID 115355)
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As previously mentioned, NTBC is a potent inhibitor of 4-HPPD and works
effectively in reducing the toxic levels of FAA and SA. However, it instead increases the
plasma tyrosine levels, effectively transforming TTI phenotype into TTIII phenotype.
Lindstedt and Holme proposed that NTBC could be used as a potential treatment for TTI.
After a formal request in October of 1989, Zeneca provided NTBC to Lindstedt’s lab and
a small number of TTI patients in Sweden were given the drug. The results were
dramatic, and the five patients that were given this drug quickly improved, with their
liver function markers returning close to normal. In 1992, Zeneca Laboratory patented
NTBC for worldwide use for the treatment of TTI and trademarked this medication as
Orfadin®. The FDA approved Orfadin® in the United States 10 years later in 2002.

1.2.1 Long-term treatment with NTBC results in neurocognitive changes.
The addition of NTBC to the clinical market has changed the prognosis for those
with TTI, allowing patients to survive into adolescence and adulthood. However, since
being on the market in the U.S. for over a decade, multiple sources have reported
neurocognitive changes following long-term therapy of NTBC (Bendadi et al, 2013,
Pohorecka et al, 2012, Masurel-Paulet et al, 2008, Thimm et al, 2012). There are a
variety of ways to evaluate normal neurological function in infants, children, and adults.
It is important to note that the appropriate test battery must be used in order to receive an
accurate representation of that individual’s intellectual functioning. There have been
multiple tests utilized in the evaluation of these patients examined in multiple studies
presented below. Important evaluations to consider involve motor abilities, Intelligence
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Quotients (IQ), and logopedic evaluations, all of which have been shown to be affected
after long-term treatment with NTBC (Thimm et al, 2012).
Thimm et. al. (2012) completed a study using standardized test batteries for
development, intelligence, and movement as well as MRIs to assess neurocognitive
development in children with TTI that had been under long-term treatment with NTBC.
Because of the rarity of the disease, the sample size was low. Only nine patients, seven
males and two females, with varying backgrounds were assessed. They had varying ages
with a range of 1 year to 9 years, with a mean age of 4.1 years old. After providing
standardized psychometric test batteries measuring both cognition and development to
the subjects, they were able to conclude that there was an abnormality in intellectual
development present in this group higher than that normally observed. This was
illustrated by five out of seven patients assessed exhibiting subpar IQs as well as an
abnormality in motor functions in four out of the seven patients. In this study, they
reported that almost 3/4 or 71% of the children had IQ scores that were below average (<
100) and one patient had an IQ less than 50, indicating mild to moderate mental
disability. Additionally, four out of seven patients assessed or 57% had below normal
movement functioning where three of those patients were classified as in need of urgent
intervention. The MRI and logopedic results were negative and inconclusive,
respectively. Although language development was retarded in one of the nine patients,
half of the sample size could not be assessed because of language barriers (Thimm et. al.,
2012)
Perhaps the strongest evidence for NTBC affecting neurological functioning was
a long-term study conducted by Bendadi et. al. (2013). When comparing IQ levels
11

between the patients and their unaffected sibling, Bendadi found TT1 patients had
significantly lower scores. In fact, it was found that when the participants were examined
multiple times over 20 years, the average drop of IQ per participant was 27 points
(Bendadi et al, 2013) , illustrated in Figure 1.3.
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Figure 1.3: Long Term treatment with NTBC lowers IQ
Longitudinal study of IQ on patients 1,4,5,7, & 8 evaluated multiple times for over 240
months. During this time, the study revealed an average decline in IQ of 27 points
(Bendadi et al., 2013).
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As mentioned above, the variety of test batteries and low sample sizes could have
an effect on the data presented. Pohorecka et. al. used a unique approach in their study.
In addition to assessing the TTI participants through standard test batteries, they also
developed a survey aimed at pinpointing behavioral issues that may not be visible in a
clinical setting, and distributed them to the parents. It was found that TTI children have
difficulties in school, paying attention and “living up to their potential” (Pohorecka et al,
2012). In addition, the parents surveyed indicated their child displayed impulsive
behavior (Pohorecka et al, 2012). In fact, the parents often said that it was not really
learning that is affected, as much as the application of the lesson. This indicates that the
problem lies in cognition and deeper thinking.

1.3

Purpose of Study and Hypothesis
Without intervention, TTI patients display chronically high levels of toxic

metabolite intermediates, mainly FAA and succinylacetone SA. Large concentrations of
the highly reactive metabolite FAA have been strongly linked to the liver and kidney
disorders that TTI patients frequently present. Most TTI patients without intervention
will succumb to liver or kidney disease usually within the first couple years of life, with
the severity of the disease being dependent on the FAH mutation site.
NTBC has been on the market over a decade in the United States, extending the
life of the patient and allowing for long-term data involving TTI patients to be finally
available. In recent years, multiple studies have reported that some TTI patients that are
on long-term therapy of NTBC experience behavioral and intellectual changes (Bendadi
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et al, 2013, Pohorecka et al, 2012, Masurel-Paulet et al, 2008, Thimm et al, 2012). These
changes are highly variable and have ranged from mild mental retardation and sub-par
IQs (Bendadi et al, 2013) to ADD-like behavior and attention issues in school age
children (Pohorecka, 2012). In addition, problems involving motor abilities have also
been reported in about half of the patients in a German study (Thimm et al, 2012).
Although NTBC almost completely rids the body of the toxic intermediates FAA
and SA, instead the individuals are left with high levels of tyrosine. Much has been
proposed on the effects of hypertyrosinemia in the brain, but there is no clear
identification of the pathophysiological mechanism for which the neurocognitive changes
take place. This chronic hypertyrosinemia, present in NTBC treated TTI patients, is the
suspected causality for the mental delay detailed in the current literature. Although
tyrosine has been implicated as the possible culprit, there has been no link established
between the varying degrees of neurological damage and tyrosine levels (Bendadi et al,
2013). It is the aim of this study to investigate the neurocognitive changes through a
mouse model, and attempt to pinpoint a biochemical mechanism for these changes
through in-vitro studies with a neuroblastoma cell line.
It has been suggested that hypertyrosinemia in the brain can lead to alterations in
neurotransmitters, thereby affecting cognition. However, tyrosine has not been
pinpointed as the catalyst for these changes. Tyrosine is a precursor for all known
catecholamine production, including the neurotransmitter dopamine, which is essential
for normal cognitive functioning. It is therefore possible that the elevated levels of
tyrosine observed in TTI patients could alter concentrations of catecholamines in the
brain, specifically dopamine. NTBC blocks the normal degradation of tyrosine. With
15

rising toxic levels of tyrosine accumulating in the cell and no pathway to eliminate it, the
cell may allocate the excessive tyrosine to the catecholamine pathway. Therefore, a rise
in dopamine and other catecholamine concentrations within these cells would be
expected, illustrated in Figure 1.4. Serum tyrosine is abnormally high in patients taking
NTBC (Thimm et. al., 2012). Tyrosine and tryptophan use the same transporter to cross
the blood brain barrier (BBB) and when tyrosine levels are high they could be competing
for entry into the brain. Alterations in tryptophan concentrations within the brain could
result in disruption of serotonin homeostasis. Cognition, which primarily takes place in
the prefrontal cortex, is very sensitive to changes in neurotransmitter homeostasis.
Furthermore, the dopaminergic and serotoninergic systems in the brain interact heavily
and can modulate each other’s activities. If one of these neurotransmitters has
uncontrolled production and release, cognition processes that require their use could be
impaired.
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Figure 1.4: Proposed biochemical consequences of NTBC on Catecholamines
Phenylalanine is converted to tyrosine through phenylalanine hydroxylase (PAH). In the
brain, tyrosine is a precursor for dopamine, norepinephrine (NE), and epinephrine
production. Tyrosine is converted to L-dopa via tyrosine hydroxylase (TH), then
converted in dopamine via dopa decarboxylase (DDC). Dopamine can be further
modified to result in NE and epinephrine through dopamine beta-monooxygenase (DBH)
and phenylethanolamine N-methyltransferase (PNMT) respectively. NTBC blocks
Hydroxyphenylpyruvate dioxygenase (4-HPPD), leading to a subsequent increase in
tyrosine. With the normal tyrosine breakdown pathway blocked by NTBC and rising
concentrations of tyrosine, the cell funnels the excess tyrosine to make catecholamines.
The result could be an increase in dopamine, norepinephrine, and epinephrine.
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In this study, the effects of NTBC on neurotransmitters critical to cognitive
functioning were assessed. This was executed by exposing a neuroblastoma cell line
(SK-N-SH), known for its dopaminergic characteristics, to NTBC in culture. Following
exposure, concentrations of dopamine, serotonin, γ-Aminobutyric acid (GABA), and
norepinephrine (NE) were assessed. Additionally, to study the effects of NTBC in vitro,
a mouse model was utilized. Behavioral assays were performed on genetically modified
mice that have a FAH mutation, used as a TTI animal model, and are on NTBC
pharmacotherapy. Additionally, wild type (WT) mice behavioral functioning will also be
assessed both on and off of NTBC. Following the behavioral assays, the mice plasma
dopamine and serotonin levels were determined. Because of the evidence presented in
the studies mentioned above, it was expected that TTI mice on NTBC would have lower
performance in cognition and memory when compared to their WT littermates.
Additionally, it was expected that their monoamine concentrations would be altered.
Not only can tyrosinemia patients benefit from research involving NTBC, it has
been utilized since its approval for a multitude of diseases. It has been suggested that
phenoketonuria (PKU) patients could benefit from the usage of NTBC, as well as
alkaptunuria and type I oculocutanous albinism. NTBC has already been approved for
use to treat alkapturnuria, and FDA clinical trials are currently recruiting for type I
oculocutanous albinism (FDA.gov). If the hypertyrosinemia associated with NTBC is in
fact identified as the source of neurocognitive decline then recommendations and
alterations in the drug must be made immediately. It is imperative to investigate potential
adverse effects of FDA approved medications, especially drugs that been on the market
for a short time. Even with pharmacotherapy with NTBC, TTI is a very devastating
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disease and has no cure. It is the responsibility of biomedical researchers to aid infants,
children, and adults that are affected. Advances in pinpointing the exact physiological
mechanism could affect the outcome of the treatment that the patient receives and their
prognosis.

1.4

Hypertyrosinemia and Neurotransmitter Activity
A novel effect of NTBC therapy is a marked increase in tyrosine concentrations in

serum, CSF, and brain tissues (Lock et al, 1998). This chronically elevated tyrosine
could have negative effects that are contributing to the cognitive changes that have been
documented and provide insight into the pathophysiology of hypertyrosinemia.
Hypertyrosinemia is observed in diseases involving tyrosine metabolism especially TTIII
and TTI patients on NTBC, and thus studies have aimed to investigate the effects of
tyrosine on the central nervous system and neurophysiology. Studies have shown that
high levels of tyrosine in vivo can increase oxidative stress measures as well as increase
the activity acetylcholinesterase in rats (Macêdo et al, 2013 & Ferreira et al, 2012). In
addition, some researchers have gone so far as to study the effect of the hypertyrosinemia
on neurotransmitter activity.
Administration of L-tyrosine into the brain of rats resulted in an increase in
oxidative stress factors (Macêdo et al, 2013). In this Brazilian study, 30-day-old rats
were injected with either 10 µg/g L-tyrosine or a saline solution, and then sacrificed via
decapitation one hour following injection (Macêdo et al, 2013). The cerebellum, stratum,
and hippocampus were all excised from the brain and examined for common markers of
oxidative stress. The results indicated that the elevation of various parameters such as
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protein carbonyls, superoxide dismutase activity, and thiobarbituric acid species
(TBARS) levels conclude that acute L-tyrosine administration does induce oxidative
stress (Macêdo et al, 2013). Protein carbonyls, superoxide dismutase, and catalase
activity were all modified in brain tissue when compared to controls (Macêdo et al,
2013). Carbonyl levels were elevated in all three-tissue types collected, while the TBARS
level was elevated in the hippocampus, a brain structure critical to memory (Macêdo et
al, 2013). Not only did the results indicate that there was an increase in oxidative stress
parameters, there was also a decrease in the antioxidant defense system as well,
potentially exacerbating the damage (Macêdo et al, 2013). This could indicate that the
neurons are under stress, and are unable to adapt to the stress through the production of
antioxidants. Oxidative stress can lead to tissue damage and damage of biological
molecules including DNA, proteins, and lipids. The authors concluded that elevated
oxidative stress parameters could be causing damage to proteins and lipids with the
increase in carbonyl compounds potentially forming aggregates inside the cell leading to
“widespread cellular dysfunction” (Macêdo et al, 2013). Additionally, dopamine is
known to undergo autoxidation in the cell, potentially leading to a disruption of normal
proteomic cellular processes. It is plausible that high cellular levels of dopamine, due to
an increase in the precursor being available, could be the cause of the increasing levels of
the autoxidation of dopamine.
An increase in L-tyrosine has been found to affect the cholinergic system. The
neurotransmitter acetylcholine has been linked to cortical activation, attention, memory,
motor tone, and learning, all of which are altered in tyrosinemia patients that exhibit
hypertyrosinemia. Furthermore, the cholinergic and dopaminergic system have an
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intimate relationship in neuronal development, specifically the connectivity, maturation,
and activation of synapses (Ferreira, 2012). In another Brazilian study, after being
administered 500 mg/kg L-tyrosine either in a single dose (acute) or every 12 hours for
24 days (chronic), rats exhibited elevated levels of the enzyme that breaks down
acetylcholine, acetylcholinesterase (AChE) (Ferreira et al, 2012). This was true for all
tissue samples collected in the study, including cortical, hippocampal, striatal tissue, as
well as serum. Also, interestingly, the mRNA expression of the ache in the
hippocampus and striatum was decreased after exposure to both acute and chronic Ltyrosine (Ferreira et al, 2012). One can then conclude that there will be a markedly
decrease in the amount of acetylcholine available in the synapse of the neuron, potentially
interrupting its role in the memory process. It was proposed that the increase in AChE is
due to the dopaminergic system, with the high tyrosine affecting dopamine levels in turn
affecting the cholinergic system (Ferreira et al, 2012). The decrease in mRNA
expression, which was only found in rats receiving chronic administration of L-tyrosine,
could be a result of negative feedback (Ferreira et al, 2012).
In addition to investigating the role of hypertyrosinemia, there have been studies
that have investigated the role of neurotransmitter concentrations in TTI patients
exhibiting neurocognitive defects. Thimm et. al. (2011) researched the effect of NTBC
on dopamine and serotonin metabolism. Although there were no significant findings
associated with dopamine levels, this study only analyzed the concentration of
homovanillic acid (HVA), a metabolite of dopamine (Thimm et al., 2011). There were,
however, changes in the concentration of a serotonin metabolite, 5-hydroxyindoleacetic
acid (5-HIAA) (Thimm et al., 2011). They describe the reduction in this serotonin
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metabolite as a decrease in serotonin turnover, and the authors point to increased CSF
concentrations of tyrosine responsible for the reduction.

1.5

Monoamines and Cognition
One of tyrosine’s principal functions in the brain is to serve as a precursor to

catecholamine production, a group of proteins that mostly function as neurotransmitters
and neuromodulators. Dopamine, the most familiar compound of the class, has been long
studied in having an importance in mood regulation and motivational impulses.
Additionally, other catecholamines, epinephrine and norepinephrine, are essential in the
normal functioning of the sympathetic nervous system. Because tyrosine concentrations
are high in patients taking NTBC, the excess tyrosine could be altering neurotransmitter
levels, specifically the catecholamines. In addition, the dopaminergic system and
serotonergic system interact heavily in the prefrontal cortex and a balance in
neurotransmitter is essential in the development and maturation of synapses (Ferreira,
2012).
Both dopamine and serotonin cannot pass the BBB, so the brain must make these
compounds locally. Serotonin is synthesized in the raphe nuclei, which constitutes part of
the reticular formation. Dopamine production can be found in a midbrain structure, the
substansia nigra (SN) that can be visualized as a dark color due the production of
neuromelonin (Iversen et. al., 2010). It is a principal part of the basal ganglia, a structure
that has heavy influence on the frontal cortex. The SN has heavy input from the striatum
in the form of two pathways: the indirect and direct. Here the striatum exerts its control,
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either having an inhibitory or excitatory effect on the neurons in the SN, specifically the
pars reticulate. In addition to the SN, dopamine-secreting neurons can be found in the
hippocampus, prefrontal cortex, and nuclueus accumbens (NA). The NA has been shown
to have inputs from the ventral tegmental area (VTA) and glutamate neurons in the
hippocampus, a structure that has been long implicated in having an effect on the
formation of new memories.
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Figure 1.5: Serotonin and Dopamine Neurophysiology.
Serotonin (left) is made in the raphe nuclei with most of its projections leading to the
cerebral cortex and cerebellum. Dopamine (right) is produced in the substansia nigra and is
then distributed to many brain structures including the prefrontal cortex and the striatum where
it exerts its control (www.CNSForum.org).
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The physiology of the dopaminergic/serotonergic systems is very complex. The
dopaminergic system in the brain can be divided into three categories based on anatomy
and physiology: the mesolimbic, nigrostriatal and mesocortical loops. The mesolimbic
loop includes the VTA and part of the striatum, the NA. Additionally, in the mesolimbic
loop of dopamine neurotransmission, Acetylcholine interneurons provide a modulary
affect on motivational behavior (Ferrieira et al. , 2012). The striatum is then connected to
the substansia nigra through the nigrostriatal pathway. Finally, the mesocortical pathway
provides connects from the midbrain in the VTA to frontal lobe structures. Serotonin can
modulate dopamine activity, which is evident in many serotonergic neurons projecting to
dopaminergic structures such as the VTA and SN (Iversen et. al., 2010). Additionally,
the cholinergic system is a neuromodulator of the dopaminergic system, which can be
illustrated by many projections from the pons to dopaminergic structures such as the
ventral tegmental area and the substansia nigra (Ferreira et. al. , 2012).
The neurotransmitter dopamine has long been recognized as having a large role in
working memory and executive function in the prefrontal cortex. However, the
interactions that dopamine has with other neurotransmitters and their receptors, such as
GABA and glutamate, demonstrates that dopaminergic function is complex. It is
impossible to argue when dopaminergic function is restored, cognitive functioning
increases. Additionally, due to the complex interactions between neurotransmitters,
abnormal levels of one compound can have a cascading effect in neurotransmitter
physiology and lead to disruptions of normal processes.
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1.6

Barnes’ Maze
As a consequence of sharing 95% of our genome with mice, many of the

physiological processes that occur in mice are similar to those of humans. In fact, mice
have been utilized for over a century as an essential animal model in the investigations of
behavioral and physiological modifications in humans. Although homology of structure
and function is not absolute between species, the ease at which genetic modifications can
be made and studied in mice makes them an attractive candidate in biomedical research
and research in drug efficacy.
In 1977, Carol Barnes investigated the effect of the senescent brain on spatial
learning and memory in rats. Her research and maze protocol was revolutionary, and
created a precedent in the study of hippocampal dependent spatial learning and memory.
Although the Morris Water Maze (MWM) has been used in the past as a tool in
investigating spatial learning in mice, its use of water and swimming can cause the
animal to experience anxiety. The Barnes’ maze eliminates the use of water and thus has
been widely utilized in areas of research sensitive to the release of corticosteroids. The
Barnes’ maze is an elevated circular platform with 16-20 holes arranged equally spaced
from each other around the circumference of the platform. The object of the maze is to
locate the placement of an escape hole, and to remember that location on subsequent
trials. Similar to the MWM, the Barnes maze is dependent on the use of visual cues, such
as colored shapes, so that when the animal is placed on the platform facing a random
direction, it is able to orient itself. Rodents have an innate response to avoid the open
brightly lite areas of the platform and are motivated to seek shelter in a dimmer area. The
Barnes’ maze takes advantage of this response and uses aversive stimuli, such as bright
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light or an obnoxious sound, to serve as the motivation for the animal to locate the one
hole that leads to an escape box under the platform. Normally, a rodent can be
conditioned to locate the hole successfully after navigating the maze a few times, and will
go directly to the hole in subsequent trials. After the animal has been conditioned to
locate the correct escape hole, the experimenter can test memory (retention) after a short
recess from the maze, usually a couple days. In addition, to further test memory and
cognitive flexibility, the experimenter can also perform a reversal probe test by moving
the escape hole either 90° or 180° from the original position of the hole (Barnes, 1977).
Although it is still unclear the exact role the hippocampus plays in learning and
memory, disruptions of normal spatial navigational functioning within the hippocampus
results in modified behavior in the Barnes’ maze. This has been demonstrated many times
through a correlation between lesions made in the hippocampus of experimental animals
and their impaired performance in the Barnes’ maze (Paylor et. al., 2001). Memory
processing and storage occurs in the hippocampus, presumably through the process of
long-term potentiation (LTP). This is a process by which the synapse is strengthened
through repetitive stimulation. Dopamine has an instrumental role in this process and
recently D1 and D5 receptors have been shown to facilitate the induction of LTP in the
hippocampus (Roggenhofer et. al., 2010). Because of the importance of dopamine in
hippocampal dependent memory, it is an attractive assay for studying changes in the
brain due to modifications in dopamine physiology.
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CHAPTER TWO

METHODS
2.1

Cell Culture
Catecholamine secreting neuroblastoma SK-N-SH cell line was purchased from

atcc.org. Eagle’s Minimum Essential Medium (EMEM), purchased from atcc.org, was
supplemented with 10% Fetal Bovine Serum and 100 µg/mL of Penicillin/Streptomycin.
Cells were grown at 37° C with 5% Carbon Dioxide. Media was renewed every three to
four days and subcultured after no longer than 10 days.

2.2

NTBC Stock Solution
10 mM NTBC stock solution was prepared by dissolving 22.2 mg sodium

bicarbonate and 13.2 mg NTBC in 4.01 ml of deionized water. Stock solution was then
passed through a microbiological filter and 1 ml aliquots were prepared and stored at 4°C
until use.

2.3

Cell Culture Neurotransmitter Assays
For neurotransmitter analysis, SK-N-SH cells were seeded in T-25 flasks and

grown for 1, 3, or 5 days incubated with 2 µM NTBC. Following incubation, cells were
processed and stimulated to release stored neurotransmitters. First, media was removed
from culture flasks, and cells were washed with prepared loading buffer and incubated at
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37° C for two minutes. Following three series of washes with 1 ml of loading buffer, 1
ml of depolarization (high K+) buffer was added. Flasks were incubated for 2 minutes at
37° C with the depolarization buffer. Supernatant was collected and stored at 20° C until
further analysis. Table 2.1 and 2.3 detail the ingredients of loading and depolarization
buffers.

Table 2.1
Loading Buffer
Ingredient

Concentration

NaCl

135 mM

KCl

5 mM

Na2HPO4

1.3 mM

D-glucose

6 mM

HEPES

10 mM

Sodium Ascorbate

0.2 mM

MgCl2

0.6 mM

CaCl2

2.5 mM

BSA

0.01%
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Table 2.2
Depolarization Buffer
Ingredient

Concentration

NaCl

135 mM

KCl

100 mM

Na2HPO4

1.3 mM

D-glucose

6 mM

HEPES

10 mM

Sodium Ascorbate

0.2 mM

MgCl2

0.6 mM

CaCl2

2.5 mM

BSA

0.01%

Dopamine, Serotonin, Norepinephrine, and GABA ELISA LDN detection kits
were purchased from Rocky Mountain Diagnostics and stored appropriately until their
use. Neurotransmitter analyses were performed on the supernatant collected after
depolarization and protocol was completed according to kit instructions.

30

2.4

Animal Husbandry
All animal subjects were cared for and treated according to IACUC approval.

Genetically modified FAH heterozygote mice were purchased Jackson Laboratory.
Heterozygotes were then breed to obtain FAH -/- mice. Mice were divided into 3 groups
based on FAH genetics and NTBC administration. FAH -/- mice were maintained on 7.5
mg/L NTBC in their drinking water. NTBC WT mice also had 7.5 mg/ L NTBC added
to their drinking water, while some WT mice drinking water did not contain any NTBC.
Mouse chow was purchased from Harlan Laboratories.

2.5

Barnes’ Maze

2.5.1 Apparatus Setup
Arena consisted of an elevated circular platform with a height of 90 cm and a 91
cm diameter. Around the arena’s circumference, there were 20 equally spaced holes with
a 5 cm diameter. One of the 20 holes contained a dark sunken compartment that serves
as the escape box. In order to create a mildly aversive environment, six 150 W
floodlights were aimed at the maze in such a way to serve as motivation for the mice to
navigate the maze/locate the escape box and minimize shadows that could interfere with
the data acquisition. The arena of the maze was surrounded with plastic dividers so that
the mice were not distracted by the experimenters’ actions and/or distal cues. Four
proximal cues (square, circle, triangle, cross) were attached to the dividers in equal
spacing so that the mice were able to orient their direction.
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Figure 2.1: Barnes’ Maze Arena.
Arena consists of an elevated circular platform with a height of 90 cm and a 91 cm
diameter. There are 20 equally spaced holes around the arena’s circumference, with one
hole containing an escape box (denoted in red). Three sets of two 150 W floodlights were
aimed at the arena in such a way to serve as motivation for mice to navigate the
maze/locate the escape box and minimize shadows that could interfere with the data
acquisition. The arena of the maze was surrounded with plastic dividers so that the mice
were not distracted by the experimenters’ actions and/or distal cues. Four proximal cues
(square, circle, triangle, cross) were attached to the dividers in equal spacing so that the
mice were able to orient their direction.
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2.5.2 Protocol
The object of the protocol was for the test mouse to be conditioned to locate the
escape hole, through four days of training, three trials each day. After four days of
training and a two day recess, the test mouse was then subjected to a single trial in order
to evaluate its retention of the location of the escape box. Finally, the day following the
retention test, the escape box was moved 90° from its original location, and the mice
were tested again.
Before the start of a trial, the test mouse was first transferred from its home cage
in the colony room to a holding box where it was then moved to the test room. Once in
the test room, the mouse was left in the holding box for one minute. On the first day of
training only, the test mouse was immediately placed in the escape box for four minutes
to serve as an adaptation period. Following adaptation, the mouse was placed back into
the holding box for an additional minute before being relocated to the maze arena. Then
the mouse was placed in start box facing a preselected random direction in the center of
the maze for 30 seconds prior to the beginning of the trial.
The trial began 30 seconds after the mouse was placed in the start box in the
center of the maze. The experimenter lifted the box, allowing the mouse to freely
navigate the platform. The trial ended when the mouse correctly locates/enters the escape
box and all four legs of the mouse were absent the platform. If the mouse is unable to
locate the hole within four minutes, the trial was terminated. The experimenter then
gently led the mouse to the escape box. Once the mouse either located or was led to the
escape box, one minute is allowed to pass before the mouse was transferred back into the
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holding box. Following each trial during training, the mouse was placed in its home box
for two minutes before beginning subsequent training trials. Between mice, the maze
was sanitized with 70% isopropyl alcohol to not allow subsequent mice to use scent
trails.
The movements of the mice were tracked during acquisition using EthoVision®
XT tracking software. Data recorded during acquisition included errors, time (latency),
distance traveled, velocity, and strategy utilized. Errors, latency, and distance were
described as primary or total, with primary being the first time the mouse locates the
escape box and total referring to the mouse entering the escape box. The strategies were
assigned according to the criteria detailed in Table 2.3.
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Table 2.3
Barnes’ Maze Qualification for Assigning Strategy

2.6

Strategy Number

Classification

Qualifications

1

Random

Unsystematic crossing the
center 3 or more times

2

Serial/Random

3 or more holes skipped
while crossing through the
center 1-3 times

3

Serial

Skipped 2 or less holes
never crossing through the
center of the arena

4

Spatial

Makes no more than ±3
errors relative to the target
hole.

Biochemical Mouse Assay
Plasma samples were collected from mice assigned to the following three

categories: FAH +/+ on NTBC, FAH +/+, and FAH -/- on NTBC. Blood was obtained
via intracardiac puncture following a lethal exposure to CO2 and cervical dislocation.
Collected blood was immediately transferred to a tube containing lithium heparin to
prevent coagulation, and spun down for 5 minutes at 1.5 g. Following centrifugation,
plasma was diluted 1:4, 1:5, or 1:6 with a sterile 0.9% sodium chloride solution to make a
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final volume of 400 µl. The diluted plasma was transferred to a labeled eppendorf tube
and stored at -20 °C until further analysis. Upon neurotransmitter analysis, samples were
thawed and the appropriate amounts of plasma were used per ELISA kit protocol.
Dopamine and serotonin measurements were determined via LDN ELISA kits purchased
from Rocky Mountain Diagnostics. Tyrosine measurements were determined using
Biovision colorimetric assay.
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CHAPTER THREE

RESULTS

3.1

The effect of NTBC on SK-N-SH cell line’s capacity to release
neurotransmitters
Following incubation with 2 µM NTBC, SK-N-SH cells were stimulated to

release stored neurotransmitters. After exposure to the depolarization buffer, the
supernatant was evaluated for neurotransmitter concentrations using LDN ELISA kits.
The results of the dopamine ELISA revealed that after SK-N-SH cells were incubated
with 2 µM NTBC for 1 or 4 days, they released more dopamine than cells that were not
incubated with NTBC, shown in Figure 3.1. Specifically, flasks incubated with 2 µM
NTBC released on average 2971.0 ± 460.4 pg/ml of dopamine (n=2, σ =1127.7), while
control flasks released 463.0 ± 190.4 pg/ml of dopamine (n=2, σ =466.5) (***p <
0.0005). The amount of dopamine released after days 1 and 5 of exposure were similar
and thus were combined.
ELISA was also performed to determine the concentrations of serotonin (5HT),
GABA, and norepinephrine, with and without NTBC incubation. All results revealed no
change between control flasks and flasks incubated with 2 µM NTBC, illustrated in
Figure 3.2, Figure 3.3 and Figure 3.4. The concentration of 5HT following 2 µM NTBC
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exposure was 4.519 ± 0.58 ng/ml 5HT (n=2, σ =1.422) compared to 4.020 ± 1.11 ng/ml
5HT (n=2, σ =2.725) in flasks that were not treated with NTBC. GABA concentrations
following 2 µM NTBC exposure were 17.17 ± 2.494 ng/ml GABA (n=2, σ =6.11)
compared to 11.72 ± 2.685 ng/ml GABA (n=2, σ =6.58) in the control flasks. The
concentration of NE following 2 µM NTBC exposure was 8.322 ± 1.520 ng/ml NE (n=2,
σ =3.72) compared to 9.920 ± 1.696 ng/ml NE (n=2, σ =4.15) in the control flasks.
Therefore, NTBC increases dopamine release in SK-N-SH cells, but has no effect on
serotonin, GABA, and norepinephrine concentrations in SK-N-SH cultures.
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***p < 0.0005
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Figure 3.1: NTBC increases SK-N-SH cell line’s capacity to release dopamine.
SK-N-SH neuroblastoma cells were seeded in 35mm flasks, and were incubated with 2
µM NTBC (n=2) or diH2O (n=2) mixed with regular media for 1 or 5 days. Data from
days 1 and 5 were similar so they were combined. Following incubation, flasks were
exposed to a high K+ physiological buffer in order to stimulate depolarization. Flasks
that were incubated with 2 µM NTBC had an increase (542%) in dopamine release
following depolarization (***p < 0.0005). Specifically, flasks incubated with 2 µM
NTBC released on average 2971.0 ± 460.4 pg/ml of dopamine (n=2, σ =1127.7), while
control flasks released 463.0 ± 190.4 pg/ml of dopamine (n=2, σ =466.5).
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Figure 3.2: NTBC has no effect on SK-N-SH cell line’s capacity to release serotonin.
SK-N-SH neuroblastoma cells were seeded in 35mm flasks, and were incubated with 2
µM NTBC (n=2) or diH2O (n=2) mixed with regular media for 1 or 5 days. Data from
days 1 and 5 were similar so they were combined. Following incubation, flasks were
exposed to a high K+ physiological buffer in order to stimulate voltage-gated
depolarization. The concentration of 5HT following 2 µM NTBC exposure was 4.519 ±
0.58 ng/ml 5HT (n=2, σ =1.422) compared to 4.020 ± 1.11 ng/ml 5HT (n=2, σ =2.725).
Therefore was no significant difference observed in serotonin release when comparing
control flasks and flasks treated with NTBC.
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Figure 3.3: NTBC has no effect on SK-N-SH cell line’s capacity to release GABA.
SK-N-SH neuroblastoma cells were seeded in 35mm flasks, and were incubated with 2
mM NTBC (n=2) or diH2O (n=2) mixed with regular media for 1 or 5 days. Data from
days 1 and 5 were similar so they were combined. Following incubation, flasks were
exposed to a high K+ physiological buffer in order to stimulate depolarization. The
concentration of GABA following 2 µM NTBC exposure was 17.17 ± 2.494 ng/ml
GABA (n=2, σ =6.11) compared to 11.72 ± 2.685 ng/ml GABA (n=2, σ =6.58). There
was no significant difference in GABA release between the controls and flasks treated
with NTBC.
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Figure 3.4: NTBC has no effect on SK-N-SH cell line’s capacity to release
norepinephrine.

SK-N-SH neuroblastoma cells were seeded in 35mm flasks, and were incubated with 2
mM NTBC (n=2) or diH2O (n=2) mixed with regular media for 1 or 5 days. Data from
days 1 and 5 were similar so they were combined. Following incubation, flasks were
exposed to a high K+ physiological buffer in order to stimulate depolarization. The
concentration of NE following 2 µM NTBC exposure was 8.322 ± 1.520 ng/ml NE (n=2,
σ =3.72) compared to 9.920 ± 1.696 ng/ml NE (n=2, σ =4.15). There was no significant
difference in NE concentrations between the controls and flasks treated with NTBC.
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3.2

Mice treated with NTBC have altered biochemistry

Mice were divided into 3 groups based on FAH genetics and NTBC
administration. FAH -/- mice were maintained on 7.5 mg/L NTBC in their drinking
water. NTBC WT mice also had 7.5 mg/ L NTBC added to their drinking water, while
some WT mice’s drinking water did not contain any NTBC. After the mouse plasma was
obtained, it was evaluated for tyrosine, dopamine, and serotonin concentrations. Figure
3.5 illustrates that when treated with NTBC, mice have 3.5X more tyrosine present in
their plasma when compared to mice not on NTBC therapy (*p < 0.05). Specifically,
mice that had NTBC added to their drinking water had tyrosine plasma concentrations on
average of 758.4 ± 230.5 µmol/L tyrosine (n=7, σ =609.8), while mice without NTBC
administration had on average 213.6 ± 69.99 µmol/L tyrosine (n=7, σ =185.16).
Although there were no significant differences in dopamine and serotonin plasma
concentrations between groups, NTBC FAH -/- mice had reduced amounts of each of the
above neurotransmitters, shown in Figure 3.6 and Figure 3.7. Dopamine concentrations
in both WT and FAH -/- mice on NTBC were reduced when compared to WT mice not
on NTBC. Healthy mice not on the drug had plasma dopamine concentrations of 360.5 ±
153.7 pg/ml dopamine (n=4, σ =307.5), healthy mice on NTBC had plasma dopamine
concentrations of 209.26 ± 66.52 pg/ml dopamine (n=5, σ =148.75), and diseased mice
on NTBC had the lowest plasma dopamine concentrations of 48.25 ± 27.17 pg/ml
dopamine (n=5, σ =60.75). 5HT plasma concentrations in both WT and FAH -/- mice on
NTBC treatment were reduced, when compared to healthy mice not on NTBC, shown in
Figure 3.7. Specifically, WT mice not on NTBC had 5HT concentrations of 1585 ±
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714.4 ng/ml 5HT (n=5, σ = 1593.4), WT mice on NTBC had 5HT concentrations of
339.8 ± 199.67 ng/ml 5HT (n=5, σ =446.5), and FAH -/- mice on NTBC had 5HT
concentrations of 250.9 ± 228.6 ng/ml 5HT (n=6, σ =559.8).
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*p < 0.05
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Figure 3.5: NTBC increases plasma tyrosine in mice.
Mice received either H20 (black column)(N=7), or 7.5mg/L NTBC in their drinking H2O
(gray column)(N=7). Mice were sacrificed with exposure to CO2 followed by cervical
dislocation. Blood was collected via intracardiac puncture. Plasma was immediately
collected following centrifugation. Tyrosine concentrations were measured using
colormetric assay. Both FAH-/- and WT mice that had NTBC added to their drinking
water had tyrosine plasma concentrations on average of 758.4 ± 230.5 µmol/L tyrosine
(n=7, σ =609.8), while mice without NTBC administration had on average 213.6 ± 69.99
µmol/L tyrosine (n=7, σ =185.16).
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Figure 3.6: The effect of NTBC on mouse plasma dopamine.
Mice were divided into 3 groups based on FAH genetics and NTBC administration. FAH
-/- (N=5) mice were maintained in 7.5 mg/L NTBC in their drinking water. NTBC WT
(N=5) mice also had 7.5 mg/ L NTBC added to their drinking water, while some WT
(N=4) mice’s drinking water did not contain any NTBC. Mice were sacrificed with
exposure to CO2 followed by cervical dislocation. Blood was collected via intracardiac
puncture. Plasma was immediately collected following centrifugation. Dopamine
concentrations were determined using ELISA. Healthy mice not on the drug had plasma
dopamine concentrations of 360.5 ± 153.7 pg/ml dopamine (n=4, σ =307.5), healthy mice
on NTBC had plasma dopamine concentrations of 209.26 ± 66.52 pg/ml dopamine (n=5,
σ =148.75), and diseased mice on NTBC had the lowest plasma dopamine concentrations
of 48.25 ± 27.17 pg/ml dopamine (n=5, σ =60.75).
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Figure 3.7: The effect of NTBC on mouse plasma serotonin.
Mice were divided into 3 groups based on FAH genetics and NTBC administration. FAH
-/- (N=5) mice were maintained in 7.5 mg/L NTBC in their drinking water. NTBC WT
(N=5) mice also had 7.5 mg/ L NTBC added to their drinking water, while some WT
(N=4) mice’s drinking water did not contain any NTBC. Mice were sacrificed with
exposure to CO2 followed by cervical dislocation. Blood was collected via intracardiac
puncture. Plasma was immediately collected following centrifugation. Serotonin
concentrations were determined using ELISA. Specifically, WT mice not on NTBC had
5HT concentrations of 1585 ± 714.4 ng/ml 5HT (n=5, σ = 1593.4), WT mice on NTBC
had 5HT concentrations of 339.8 ± 199.67 ng/ml 5HT (n=5, σ =446.5), and FAH -/- mice
on NTBC had 5HT concentrations of 250.9 ± 228.6 ng/ml 5HT (n=6, σ =559.8).
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3.3

FAH -/- mice treated with NTBC have reduced performance in the Barnes’
maze
Barnes’ maze trials included a 4 day training period, followed by two days rest.

The retention test consisted of one trial only. The day following the retention test, mice
were challenged in the probe where the target hole was moved 90° from its original
location. Throughout training and the retention test, there were no significant differences
made while the mice attempted to locate the target hole, shown in Figures 3.8, 3.9, and
3.10. However, during the probe trial, NTBC FAH -/- mice took significant longer time
and traveled more distance to locate the new escape hole location than their WT
littermates (**p < 0.005), illustrated in Figures 3.9 – 3.12. Specifically, in the probe, WT
mice not on NTBC were able to locate the escape hole on average in 47.60 ± 14.54
seconds (n=10, σ =45.97) and traveled on average 316.4 ± 71.88 cm (n=10, σ =227.30).
WT mice that were on NTBC located the new target hole on average in 32.63 ± 7.47
seconds (n=8, σ = 21.13) and traveled on average 219.3 ± 51.48 cm (n=8, σ =154.6).
FAH -/- mice on NTBC performed the worst of all experimental groups by taking on
average 128.13 ± 19.56 seconds (n=8, σ =55.34) and traveled on average 709.3 ± 118.9
cm (n=8, σ =336.2). However, in Figure 3.13, it is exhibited that there were no
significant differences between groups in velocity utilized during the probe trials.
Strategies were assigned according to qualifications listed in Table 3.3. Strategies
1 and 2 represent random strategies, while strategies 3 and 4 require either a serial or
spatial approach respectively. FAH -/- mice utilized the two random strategies, 1 and 2,
more than 62.5 % of the probe trials. In contrast, both NTBC WT and WT group not on
NTBC did not use strategy 1 in the probe and instead utilized higher strategies 3 and 4
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75 % and 50 % of the probe trials respectively, shown in Figure 3.14.

Finally, shown in

Figure 3.15, NTBC FAH -/- mice were more reluctant to enter the escape hole throughout
training, while their WT littermates entered the escape hole on average more than 75 %
of the trials. Specifically, WT mice both on and off NTBC entered the escape hole 75.56
± 5.352 percent of trials (n=8, σ =13.1) and 81.95 ± 7.505 percent of trials (n=10, σ
=18.38) respectively, compared to FAH -/- mice on NTBC who entered the escape hole
29.86 ± 3.940 percent of probe trials (n=8, σ =9.65).
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Figure 3.8: Primary Errors made during Barnes Maze Acquisition.
Mice were divided into 3 groups based on FAH genetics and NTBC administration. FAH
-/- (n=8) mice were maintained in 7.5 mg/L NTBC in their drinking water. NTBC WT
(n=8) mice also had 7.5 mg/ L NTBC added to their drinking water, while some WT
(n=10) mice’s drinking water did not contain any NTBC. Primary errors represent the
number of holes the mice investigated before locating the target hole. Trials included a 4
day training period, followed by two days rest. The retention test consisted on one trial
only. The day following the retention test, mice were challenged in the probe where the
target hole was moved 90°. There were no significant differences in primary errors made
between groups.
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Figure 3.9: Primary Latency during Barnes Maze Acquisition.
Mice were divided into 3 groups based on FAH genetics and NTBC administration. FAH
-/- (n=8) mice were maintained in 7.5 mg/L NTBC in their drinking water. NTBC WT
(n=8) mice also had 7.5 mg/ L NTBC added to their drinking water, while some WT
(n=10) mice’s drinking water did not contain any NTBC. Primary latency represents the
time it took for the mice to first locate the target hole. Trials included a 4 day training
period, followed by two days rest. The retention test consisted on one trial only. The day
following the retention test, mice were challenged in the probe where the target hole was
moved 90°. NTBC FAH -/- mice took significantly more time to locate the escape hole
when compared to their WT littermates both on and off of NTBC.
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Figure 3.10: Primary Distance during Barnes Maze Acquisition.
Mice were divided into 3 groups based on FAH genetics and NTBC administration. FAH
-/- (n=8) mice were maintained in 7.5 mg/L NTBC in their drinking water. NTBC WT
(n=8) mice also had 7.5 mg/ L NTBC added to their drinking water, while some WT
(n=10) mice’s drinking water did not contain any NTBC. Primary distance represents the
time it took for the mice to first locate the target hole. Trials included a 4 day training
period, followed by two days rest. The retention test consisted on one trial only. The day
following the retention test, mice were challenged in the probe where the target hole was
moved 90°. NTBC FAH -/- mice traveled more distance when compared to their WT
littermates both on and off of NTBC.
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Figure 3.11: Primary Latency during Barnes Maze Probe Trial.
Mice were divided into 3 groups based on FAH genetics and NTBC administration. FAH
-/- (n=8) mice were maintained in 7.5 mg/L NTBC in their drinking water. NTBC WT
(n=8) mice also had 7.5 mg/ L NTBC added to their drinking water, while some WT
(n=10) mice’s drinking water did not contain any NTBC. Primary latency represents the
time it took for the mice to locate the target hole. Trials included a 4 day training period,
followed by two days rest. The retention test consisted on one trial only. The day
following the retention test, mice were challenged in the probe where the target hole was
moved 90°. Specifically, in the probe, WT mice not on NTBC were able to locate the
escape hole on average in 47.60 ± 14.54 seconds (n=10, σ =45.97). WT mice that were
on NTBC located the new target hole on average in 32.63 ± 7.47 seconds (n=8, σ =
21.13). FAH -/- mice on NTBC performed the worst of all experimental groups by
taking on average 128.13 ± 19.56 seconds (n=8, σ =55.34).
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Figure 3.12: Primary Distance during Barnes Maze Probe Trial.
Mice were divided into 3 groups based on FAH genetics and NTBC administration. FAH
-/- (n=8) mice were maintained in 7.5 mg/L NTBC in their drinking water. NTBC WT
(n=8) mice also had 7.5 mg/ L NTBC added to their drinking water, while some WT
(n=10) mice’s drinking water did not contain any NTBC. Primary distance represents the
distance traveled for the mice to locate the target hole. Trials included a 4 day training
period, followed by two days rest. The retention test consisted on one trial only. The day
following the retention test, mice were challenged in the probe where the target hole was
moved 90°. Specifically, in the probe, WT mice not on NTBC traveled on average 316.4
± 71.88 cm (n=10, σ =227.30) to find the new location of the escape hole. WT mice that
were on NTBC located the new target hole on average after traveling on average 219.3 ±
51.48 cm (n=8, σ =154.6). FAH -/- mice on NTBC performed the worst of all and
traveled on average 709.3 ± 118.9 cm (n=8, σ =336.2).
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Figure 3.13: Primary Velocity during Barnes Maze Probe Trial.
Mice were divided into 3 groups based on FAH genetics and NTBC administration. FAH
-/- (n=8) mice were maintained in 7.5 mg/L NTBC in their drinking water. NTBC WT
(n=8) mice also had 7.5 mg/ L NTBC added to their drinking water, while some WT
(n=10) mice’s drinking water did not contain any NTBC. Primary velocity represents the
distance/time it took for the mice to locate the target hole. Trials included a 4 day
training period, followed by two days rest. The retention test consisted on one trial only.
The day following the retention test, mice were challenged in the probe where the target
hole was moved 90°. All groups of mice had similar velocities when locating the new
location of the target hole.
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Figure 3.14: Strategies Utilized during Barnes Maze Probe Trial.
Mice were divided into 3 groups based on FAH genetics and NTBC administration. FAH
-/- (n=8) mice were maintained in 7.5 mg/L NTBC in their drinking water. NTBC WT
(n=8) mice also had 7.5 mg/ L NTBC added to their drinking water, while some WT
(n=10) mice’s drinking water did not contain any NTBC. Trials included a 4 day training
period, followed by two days rest. The retention test consisted on one trial only. The day
following the retention test, mice were challenged in the probe where the target hole was
moved 90°. Strategies were assigned according to qualifications listed in Table 3.3.
FAH -/- mice utilized the two worst strategies, 1 and 2, more than 50 % of the probe
trails. In contrast, both NTBC WT and WT groups did not use strategy 1 in the probe and
used strategies 3 and 4 more often than the NTBC FAH -/- mice.
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Figure 3.15: Percent Entry into Escape Hole during Barnes Maze Acquisition.
Mice were divided into 3 groups based on FAH genetics and NTBC administration. FAH
-/- (n=8) mice were maintained in 7.5 mg/L NTBC in their drinking water. NTBC WT
(n=8) mice also had 7.5 mg/ L NTBC added to their drinking water, while some WT
(n=10) mice’s drinking water did not contain any NTBC. Primary measurements were
based on when the mouse first located the target hole. Trials included a 4 day training
period, followed by two days rest. The retention test consisted on one trial only. The day
following the retention test, mice were challenged in the probe where the target hole was
moved 90°. Specifically, WT mice both on and off NTBC entered the escape hole 75.56
± 5.352 percent of trials (n=8, σ =13.1) and 81.95 ± 7.505 percent of trials (n=10, σ
=18.38) respectively, compared to FAH -/- mice on NTBC who entered the escape hole
29.86 ± 3.940 percent of probe trials (n=8, σ =9.65).
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CHAPTER FOUR

DISCUSSION AND CONCLUSIONS

4.1

NTBC causes an increase in intracellular dopamine in SK-N-SH cells
A hallmark of NTBC therapy is an increase in plasma tyrosine concentrations. It

was proposed that this increase in tyrosine, caused by the blockade of the tyrosine
breakdown pathway by NTBC, could lead to an increased production and release of
dopamine and other catecholamines. This hypothesis was tested by exposing SK-N-SH
cells to NTBC for no more than 5 days, and determining the concentrations of two
catecholamines, dopamine and NE. Additionally, it was important to determine if NTBC
had an effect on serotonin and GABA. The SK-N-SH cell line displays the biochemical
properties of neuronal cells, and also has been noted for its high tyrosine hydroxylase
activity, the rate-limiting enzyme in dopamine production (Biedler et. al., 1978). This
made the SK-N-SH cell line an attractive candidate for the experimental design described
above. SK-N-SH cells synthesized significantly more dopamine after being exposed to
NTBC for no more than five days, shown in Figure 4.1. However, when cells were
exposed to NTBC, they did not have any change in the concentrations of other
neurotransmitters tested, specifically serotonin, GABA, and NE.
The hypothesis proposed earlier can be partially accepted. NTBC did increase
dopamine synthesis in a neuroblastoma cell line, illustrated in Figure 4.1. Because
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Figure 4.1: Proposed biological consequences of NTBC on Catecholamines
(Revisited)
The hypothesis that NTBC increases catecholamines was tested by exposing SK-N-SH
cells to NTBC for no more than 4 days, and measuring the concentration of two
catecholamines, dopamine and NE. SK-N-SH cells that were exposed to NTBC released
significantly more dopamine than cells not exposed to NTBC shown in Figure 4.1. There
was not an increase in NE observed. Therefore, NTBC increases dopamine release and
production but has no effect on NE.
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NTBC blocks the normal degradation pathway of tyrosine, neurons instead will allocate
at least some of the excessive tyrosine to produce more catecholamines, specifically
dopamine. In vivo, neurons within the midbrain responsible for dopamine production
could be negatively effected by NTBC, releasing more dopamine into the synapse over
time, activating associated negative feedback loops. If this increase in dopamine
continues, this could cause dysfunction in dopamine homeostasis in the brain, a
dysfunction observed in schizophrenia. In this neurological condition, it is thought that
an increase in midbrain dopamine production disrupts dopamine mesocortical
homeostasis, and reduces the availability of dopamine to the frontal cortex (Brisch et. al.,
2014). This has been described as the likely cause of the cognitive impairment associated
with the disease, including memory loss and delayed cognition (Brisch et. al., 2014).
Additionally, serotonin, GABA, and NE concentrations after NTBC exposure were
comparable to those of flasks not exposed. Interestingly, NE levels did not increase in
flasks exposed to NTBC like dopamine. NE is mostly used by the sympathetic nervous
system to induce the “fight or flight” survival mechanism (Hardie, 1992). Although
some parts of the brain do further convert dopamine into NE and epinephrine, such as in
the locus coeruleus, most of the NE production is present in adrenal medulla as a part of
the peripheral nervous system (Hardie, 1992).
The dopaminergic system, in vivo, is modulated by each one of the above
neurotransmitters, either directly or indirectly (Giovanni et. al., 2010). However, SK-NSH cells grown in culture do not give insight into these physiological processes. Instead,
it provides understanding of how NTBC behaves within dopaminergic cells. According
to the data presented, NTBC does not have an intracellular effect on serotonin, GABA, or
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NE in SK-N-SH cell lines. In conclusion, the evidence presented above gives insight into
the biochemical consequences of NTBC in dopaminergic neurons. NTBC is affecting
the amount of dopamine being produced inside SK-N-SH cells. Negative feedback loops
associated with high dopamine release would be activated in a physiological setting. This
increase in dopamine production could have additional intracellular and physiological
consequences that could be a contributing factor in the impaired cognition described in
some TTI individuals.

4.2

Mice treated with NTBC have decreased plasma monoamine concentrations.
In order to study the effects of NTBC in vivo, a TTI mouse model was utilized.

Mice were divided into three experimental groups: NTBC FAH -/-, NTBC WT, and No
drug WT. The results of the biochemical assays revealed that when taking NTBC, mice
had significantly higher concentrations of plasma tyrosine, and marked decreases in
dopamine and serotonin levels.
It was shown that, under hypertyrosinemia conditions while on NTBC therapy,
neurons respond through high, potentially uncontrolled, synthesis of dopamine. Plasma
tyrosine measurements in mice can vary from 30 to 200 µmol/L. However, it is not until
plasma tyrosine measurements exceed 500 µmol/L that any manifestations, such as a
change in cognition, can be observed (Grompe, 2015). Mice that were not treated with
NTBC had mean plasma tyrosine levels that did not exceed this threshold. This can be
compared to mice that were taking NTBC, both WT and FAH -/-, who had mean tyrosine
concentrations of 758.4 ± 230.5 µmol/L tyrosine (n=7, σ =609.8), shown in Figure 3.5.
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This indicates that mice treated with NTBC could see clinical manifestations of
hypertyrosinemia, including a disruption in cognition.
Both groups that had NTBC in their drinking water had a marked decreases in
both dopamine and serotonin plasma concentrations. Low plasma dopamine levels are
observed in a variety of pathologies, including Parkinson’s disease and attention deficient
hyperactivity disorder (ADHD) (Iverson et. al., 2010). Both of these conditions result in
a disruption in cognition that can usually be rescued once dopamine levels are restored.
Low dopamine can cause a variety of symptoms including a decreased ability to pay
attention and impaired memory processes (Iverson et. al., 2010). Additionally,
disruptions in serotonin homeostasis can modify behavior, and have been linked to a
variety of psychiatric illnesses including depression and obsessive-compulsive disorder
(OCD) (Pittenger & Bloch, 2014). The observation of low plasma serotonin in NTBC
treated mice pairs with what Thimm et. al (2011) observed. Here, after an administration
of L-tyrosine in mice mimicking the physiological effects of NTBC, there was a
reduction of a serotonin metabolite, 5-HIAA, observed (Thimm et. al., 2011). This is
similar to what has been observed in PKU patients with cognitive delays. Coupled with
the low plasma dopamine observed, as is in PKU patients, this could indicate common
mechanisms for the cognitive impairments observed in both conditions.
It is unclear exactly why NTBC treated mice have low plasma dopamine and
serotonin. Many complex physiological processes could be in play, and more research
must be performed in order to determine this mechanism. The high plasma tyrosine,
observed in mice treated with NTBC, could have an effect on peripheral dopamine
production. Furthermore, the high plasma tyrosine could also inhibit the transport of
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phenylalanine and tryptophan into the brain. These large neutral amino acids all share a
common transporter into the brain, leading to a competition for its use (Fernstrom, 2013).
Furthermore, it was shown that high plasma tyrosine could alter the amount of tryptophan
that crosses the BBB, and the lack of tryptophan in the brain can lower serotonin
concentrations (Fernstrom, 2013). The high tyrosine coupled with low plasma dopamine
and serotonin could cause a modification in behavior in the mice taking NTBC, similar to
what is observed in some NTBC treated TTI patients.

4.3

FAH -/- mice on NTBC have decreased performance in the Barnes’ maze.
The Barnes’ maze was performed on three experimental groups (NTBC FAH -/-,

NTBC WT, No drug WT), described above. The results exhibited that NTBC FAH -/mice have decreased performance compared to the WT mice both on and off the drug.
Throughout training all three groups of mice were able to learn the location of the target
hole. However, the results of the probe trial indicated that NTBC FAH -/- could not
adapt to the new target hole location when compared to the WT groups, and thus took
longer to find the new location of the hole and traveled further distances, illustrated in
Figures 3.11 and 3.12.
The results of the probe trial reveal that NTBC FAH -/- mice took longer to find
the target hole and traveled more distance, presented in Figures 3.11 and 3.12. The probe
trial was conducted on day 8 of the Barnes’ maze protocol, where the location of the
escape hole was moved 90° from its original location. During most trials amongst
groups, mice went directly to the previous target hole location, as expected. In the probe
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trials, both sets of WT mice used both serial and spatial strategies more than 50% of the
time. During the probe, no WT mouse utilized strategy 1, the random strategy. The
NTBC FAH -/- mice, however, used the first strategy more than ½ of the probe trials. It
is for this reason that they took longer to find the new target location, in addition to
traveling further distances.
When analyzing the plasma of the mice tested, both experimental groups on
NTBC seem to have similar biochemistry. Therefore, it was expected that both groups on
NTBC therapy would have similar results in cognition tests such as the Barnes’ maze.
This was not observed; WT mice treated with NTBC did not show a reduced performance
in the Barnes’ maze when compared to healthy mice on the drug. In fact, healthy mice
both on and off NTBC had similar results in the Barnes’ maze, while the NTBC FAH-/mice struggled in the probe trial. This indicates that WT mice may have a rescue
mechanism for the excessive tyrosine and dopamine that is either absent or nonfunctional in FAH -/- mice. Furthermore, this signifies that NTBC may not be stopping
the breakdown of tyrosine completely. In WT mice taking NTBC, this would not pose
any physiological problems because tyrosine can be effectively broken down. However,
in the FAH -/- mice, tyrosine cannot be broken down because of the FAH defect. This
would lead to some residual SA and FAA production that could potentially decrease the
overall health of the individual.
All mice evaluated were able to effectively learn the location of the target hole. It
wasn’t until the escape box was moved that FAH -/- mice fell short. The probe test
measures the animal’s ability to adapt and requires a shift in attention. This adaptation
and required shift in attention requires executive function, a process that occurs in the
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frontal cortex (Iverson et. al., 2010). The frontal cortex is under heavy influence from the
dopaminergic system, as part of the mesocortical pathway, and is sensitive to changes in
dopamine functioning. The inability for the FAH -/- mice to switch tasks in the probe
test signifies that there is something present in the diseased state of the FAH -/- mice,
prevented them from being as cognitively flexible as the healthy mice on NTBC. The
high frequency of which FAH -/- mice reverted back to the random strategy in the probe
test further supports this claim.
Carol Barnes (1977) showed that dysfunction within hippocampus can lead to
disruptions in spatial learning and memory in mice through which Barnes’ maze
administration would expose. The hippocampus has long been implicated as one of the
principal brain structures involved in the formation of new memories, presumably
through the process of LTP, where the synapse is strengthened through repetitive
stimulation. This process is impaired in senescent mice, as investigated by Dr. Barnes,
which was correlated to a reduced performance in the Barnes’ maze. One particular
requirement for the facilitation of LTP is the synchronistic nature that neurons must fire.
This can be explained by the Hebbian theory, which details that the timing of firing
neurons is critical to the learning process. The high, potentially uncontrolled, release of
dopamine observed in culture when exposed to NTBC could be interfering with this
process. It seems that, although healthy mice on NTBC were able to adapt to these
changes in dopamine concentrations, the diseased mice could not, resulting in the
diminished performance in the probe test. Due to the instrumental role dopamine has in
the facilitation of LTP in the hippocampus and frontal cortex, it is likely that the
dopamine dysfunction observed plays a role in the Barnes’ maze impairment in FAH -/-
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mice. However, there could be other complex physiological processes affecting the
behavior of the NTBC FAH -/- mice. For example, a product of tyrosine metabolism, the
ketone body acetoacetate, has recently been found to play a critical role in the brain
serving as a metabolic fuel and assisting in sleep homeostasis (Chikahisa et. al., 2014).
NTBC FAH -/- mice would have reduced production and metabolism of this ketone body,
and could be susceptible to any associated negative effects.

4.4

Conclusion
NTBC, a current treatment for TTI, increases intracellular dopamine production,

alters mouse monoamine biochemistry, and when containing the TTI mutation a lower
cognitive flexibility. The results of this study have not only given insight to biochemical
consequences of NTBC intracellularly, it also demonstrated that diseased mice on NTBC
have an inability to adapt to these changes, an impairment evident in the Barnes’ maze.
A disruption in dopamine homeostasis could be a likely contributing factor to this
impairment noted in the Barnes’ maze, but more research must be conducted. Additional
factors could be in play, as cognition requires the cooperation of many complex
processes. It is imperative to have continued research into the molecular effects of this
drug, as it is being investigated for the treatment of other amino acid disorders, PKU and
alkaptonuria. Although it is clear that dopamine could be a contributing factor in the TTI
associated cognitive impairment noted in the literature, there are other factors that should
be considered. This study only “scratches the surface” in the continued journey to
discovery the neurophysiological mechanism of the disabilities detailed in the literature.
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